Last reviewed · How we verify

GLA5PR GLARS-NF1 — Competitive Intelligence Brief

GLA5PR GLARS-NF1 (GLA5PR GLARS-NF1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glutaminyl-tRNA synthetase inhibitor. Area: Oncology.

phase 3 Glutaminyl-tRNA synthetase inhibitor GLARS (Glutaminyl-tRNA synthetase) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GLA5PR GLARS-NF1 (GLA5PR GLARS-NF1) — Daewon Pharmaceutical Co., Ltd.. GLA5PR GLARS-NF1 is a glutaminyl-tRNA synthetase (GlnRS) inhibitor designed to selectively target and inhibit neurofibromatosis type 1 (NF1) mutant cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GLA5PR GLARS-NF1 TARGET GLA5PR GLARS-NF1 Daewon Pharmaceutical Co., Ltd. phase 3 Glutaminyl-tRNA synthetase inhibitor GLARS (Glutaminyl-tRNA synthetase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glutaminyl-tRNA synthetase inhibitor class)

  1. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GLA5PR GLARS-NF1 — Competitive Intelligence Brief. https://druglandscape.com/ci/gla5pr-glars-nf1. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: